Evidence map›Paper›PMID 37794855›Full record

ArticleRevista de nefrologia, dialisis y transplante : publicacion conjunta de la Asociacion Regional de Dialisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires y la Sociedad Argentina de Nefrologia

Long-term Effects of Gastric Acid Prophylaxis in Kidney Transplant Recipients.

Halil Yazici, Ozgur Akin Oto, Safak Mirioglu, Ahmet Burak Dirim, Erol Demir, Omer Uludag, Omer Faruk Akardere, Yasar Caliskan, Krista L Lentine

Open access · greenAbstract read
In one paragraph

Article in Revista de nefrologia, dialisis y transplante : publicacion conjunta de la Asociacion Regional de Dialisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires y la Sociedad Argentina de Nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Halil YaziciDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-2526-3483
Ozgur Akin OtoDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-0928-8103
Safak MiriogluDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-0362-8154
Ahmet Burak DirimDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-2262-8627
Erol DemirDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-0128-5645
Omer UludagDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0001-9928-7766
Omer Faruk AkardereDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-2865-1369
Yasar CaliskanDivision of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-3816-8047
Krista L LentineCenter for Abdominal Transplantation, Saint Louis University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-9423-4849
Istanbul University · TRSaint Louis University · US

Funding

Choosing Immune Suppression in Renal Transplantation by Efficacy and MorbidityR01DK102981 · NIDDK · WASHINGTON UNIVERSITY · PI DHARNIDHARKA, VIKAS R. · 2014 to 2018
$1.9M
NIDDK NIH HHS R01 DK102981
6 · The paper itself

Abstract

Objectives: Prophylactic acid suppression with proton pump inhibitors or H2 receptor antagonists is often administered after kidney transplantation. The Association of proton pump inhibitors or H2 receptor antagonists with acute rejection, hypomagnesemia, and graft loss in kidney transplant recipients is not well established. Material and Methods: We performed a retrospective cohort study of 302 kidney transplant recipients at one center (57% male; mean age 35.5±11.2 years) with more than 6 months post-transplant follow-up. Recipients were grouped according to gastric acid prophylaxis: only proton pump inhibitors (n=179), only H2 receptor antagonists (n=42), proton pump inhibitors and H2 receptor antagonists (n=55), and nonusers (n=26). The primary outcome was biopsy-proven acute rejection. Graft loss and hypomagnesemia were defined as secondary outcomes. Results: Nonusers were younger and mostly under steroid-free immunosuppression compared to other study groups (p=0.030 and p=0.009, respectively). The primary outcome was similar across study groups (p=0.266). Kaplan-Meier analyses also demonstrated similar 10-year graft survival rates: 95.5% for proton pump inhibitors, 97.6% for H2 receptor antagonists, 100% for proton pump inhibitors/H2 receptor antagonists, and 96.2% for nonusers (p=0.275). Conclusions: The use of proton pump inhibitors is not associated with acute rejection or graft loss but may cause mild hypomagnesemia in kidney transplant recipients.

Indexed as

acute rejectionH2 receptor antagonistshypomagnesemiakidney transplantationproton pump inhibitors

Identifiers

PMID37794855
PMCPMC10548784
OpenAlexW4387357307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.